The Cordis Endovascular Division of Cordis Corporation, announced U.S. Food and Drug Administration (FDA) approval to market its PRECISE® RX Nitinol Self-Expanding Stent and ANGIOGUARD® RX Emboli Capture Guidewire System to treat clogged neck arteries.
The Cordis Endovascular Division of Cordis Corporation, announced U.S. Food and Drug Administration (FDA) approval to market its PRECISE® RX Nitinol Self-Expanding Stent and ANGIOGUARD® RX Emboli Capture Guidewire System to treat clogged neck arteries. Cordis Endovascular also announced the initiation of SAPPHIRE Worldwide, a 10,000 patient global registry to assess the 30-day rate of major adverse events (death, stroke or myocardial infarction) following the placement of a stent in high surgical risk patients with carotid artery disease. The registry will include up to 275 centers with low, medium and high annual carotid stent implant volumes, from both academic and private hospitals.
Sanford Clinic Vascular Associates is proud to be one of the clinical sites to participate in this worldwide patient study. At Vascular Associates, nearly 80% of its patients vein related problems are already treated non-surgically. Board certified vascular surgeons, Greg Schulz, MD and Patrick Kelly, MD, are now able to use this study to widen the range and increase the number of patients that receive a minimally invasive carotid stenting procedure versus surgically removing plaque from an artery that has become blocked. Carotid Artery Disease
Carotid artery disease is the buildup of atherosclerotic plaque in the major neck vessels delivering blood to the brain, a major cause of stroke. CAS is a minimally invasive, non-surgical procedure intended to improve blood flow to the brain while helping prevent debris from entering cerebral circulation, and an important alternative for patients who are ineligible for CEA. Risk factors for carotid artery disease include advanced age, family history of stroke, plaque buildup in other areas of the body, high blood pressure, and diabetes.
The American Heart Association estimates that 20 to 30 percent of strokes are associated with carotid artery disease, caused by particles of atherosclerotic plaque traveling into the vessels that supply the brain with oxygen and vital nutrients. Stroke affects an estimated 700,000 Americans each year, making it the nations third leading cause of death, and a leading cause of serious, long-term disability. Cordis Endovascular
Cordis Endovascular is a recognized leader in endovascular research and development and is committed to serving the cardiology, radiology and vascular surgery communities through the development of groundbreaking technologies for the treatment of peripheral vascular disease. It constantly seeks solutions to the human anatomy's most challenging problems, such as carotid artery disease, superficial femoral artery disease, venous thrombotic disease, lower extremity disease and aortic aneurysm. About Cordis Corporation
Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in developing and manufacturing interventional vascular technology. Through the companys innovation, research and development, physicians worldwide are better able to treat the millions of patients who suffer from vascular disease. About Sanford Clinic Vascular Associates
Board certified vascular surgeons, Greg Schultz, MD
and Patrick Kelly, MD
, use the latest medical technology to ensure the safest, most minimally invasive treatments possible. Vascular Associates offers the most comprehensive vascular care in South Dakota, North Dakota, Iowa and Minnesota. The treatment options prescribed range from lifestyle changes to medications to surgery. Sanford Clinic Vascular Associates is located on the campus of Sanford USD Medical Center in Sioux Falls, SD. The Vascular Lab has received program accreditation from the Intersocietal Commission for the Accreditation of Vascular Laboratories (ICAVL) - a first for the North Central region.